BioScience Laboratories Announces Testing Capabilities for NDM-1
BioScience Laboratories has obtained seven clinical isolates that provide a strong model for predicting a product's efficacy against "Super-Bugs", such as the New Delhi metallo-a-lactamase 1 (NDM-1) strain.

BOZEMAN, MT, August 18, 2010 /24-7PressRelease/ -- BioScience Laboratories has obtained seven clinical isolates of Carbapenem-Resistant (CR) Klebsiella pneumoniae and Escherichia coli.

These organisms provide a strong model for predicting a product's efficacy against "Super-Bugs," such as the New Delhi metallo-a-lactamase 1 (NDM-1) strain that has aroused recent worldwide concern. Carbapenems are historically used as a last resort for fighting bacterial infections, particularly versus multidrug-resistant Gram-negative species.

The five isolates of CR-Klebsiella pneumoniae and two isolates of CR-Escherichia coli are being used by BioScience Laboratories microbiologists to test products for their in-vitro efficacy as topical antimicrobials or hard-surface disinfectants to provide data predictive of a product's efficacy versus the New Delhi metallo-a-lactamase 1 (NDM-1) strain.

Press Release Contact Information:

John Dyba
BioScience Laboratories
Senior Account Executive
300 N Willson
Bozeman, MT
USA 59715
Voice: 877-858-2754
Fax: 406-586-7930
Website: Visit Our Website